78 results on '"Connell NT"'
Search Results
2. Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease.
- Author
-
Skinner MW, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell NT, Crato M, Dargaud Y, d'Oiron R, Dunn AL, Escobar MA, Escuriola-Ettingshausen C, Gouider E, Harroche A, Hermans C, Jimenez-Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce GF, Ramos G, Recht M, Romero-Lux O, Rotellini D, Santoro RC, Singleton TC, Srivastava A, Susen S, Talks K, Tran H, Valentino LA, Windyga J, Yang R, and Mancuso ME
- Abstract
Introduction: The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF-McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology., Aim: Discuss missed opportunities and the methodological approach of the ISTH Guideline in contrast to how GRADE was previously applied in rare diseases., Methods: Critically analyse the methodology of each guideline along with best practices in the use of GRADE. Where applicable, the WFH Guidelines for the Management of Haemophilia were analysed., Results: Important differentiating features in applying GRADE were identified. Where a strong evidence base is lacking, data other than those from randomized controlled trials, which may not always be justified, need to be considered, including incorporation of outcomes important to people living with the disease. Justification and stakeholder input to prioritize questions requiring a new guideline, panel composition with necessary patient participation and content expertise were also found to be significant differentiating features., Conclusion: The puristic approach taken in the ISTH Guideline development process, without consideration of accepted adaptations to GRADE implementation, created a missed opportunity for progressing haemophilia care, leading to guideline recommendations that have been widely deemed invalid and obsolete by expert healthcare professionals and by those living with the condition, the very people who are expected to implement or bear the impact of the recommendations. Lessons learnt from this comparative analysis should guide future guideline development and encourage collaboration to further advance haemophilia., (© 2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal.
- Author
-
Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, Connell NT, Crato M, Dargaud Y, d'Oiron R, Dunn AL, Escobar MA, Ettingshausen CE, Fischer K, Gouider E, Harroche A, Hermans C, Jimenez-Yuste V, Kaczmarek R, Kenet G, Khoo L, Klamroth R, Langer F, Lillicrap D, Mahlangu J, Male C, Mancuso ME, Matsushita T, Meunier S, Miesbach W, Nolan B, Oldenburg J, O'Mahony B, Ozelo M, Pierce GF, Ramos G, Recht M, Romero-Lux O, Rotellini D, Santoro RC, Singleton TC, Skinner MW, Srivastava A, Susen S, Talks K, Tran H, Valentino LA, Windyga J, and Yang R
- Abstract
Introduction: Evidence-based clinical practice guidelines drive optimal patient care and facilitate access to high-quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from randomized controlled trials but from non-randomized and well-designed observational studies and real-world data, is challenging. The methodology used for assessing available evidence should consider this critical fact. In formulating guidelines, it is essential to include treatment goals and patient preference., Aim: This paper comprehensively critiques, against this background, the recommendations of the ISTH clinical practice guidelines for the treatment of haemophilia., Methods: Each recommendation was critically reviewed against available evidence as well as existing guidelines and commented upon for its scientific validity, impact on clinical practice and access to care globally. The validity of the way in which the GRADE methodology was applied to existing evidence was also assessed., Results: The critique provided shows that these recommendations have major limitations: they did not state treatment goals and contradict existing guidelines; opportunities for providing access to innovation were missed when the therapeutic benefits of the products approved in the last decades were not included. A major reason for this is the inappropriate adoption of the GRADE methodology without adaptations and without considering treatment goals and patient-relevant outcomes., Conclusion: These recommendations may mislead healthcare professionals, payers and governments and therefore cannot serve the patient community well. They setback the advances made in haemophilia care because they overlook important available evidence and do not guide clinical practice to contemporary standards., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
4. A core outcome set for prophylaxis and perioperative treatment of von Willebrand disease: The coreVWD initiative.
- Author
-
Clearfield E, Kim B, Ford S, Connell NT, Santaella ME, Lavin M, Degenaar-Dujardin MEL, Ayoub E, Flood VH, Rotellini D, Skinner MW, and James P
- Abstract
Introduction: Treatment options are expanding for von Willebrand disease (VWD). A core outcome set (COS)-a minimum set of agreed-upon outcomes to be used in every clinical trial for a given condition-provides guidance on which outcomes are most important to measure to ensure necessary data is collected for a variety of stakeholders and enable comparison across products and trials., Aim: coreVWD aimed to develop a COS for trials for prophylaxis and perioperative treatments for VWD., Methods: A modified Delphi consensus process was used to condense/prioritize a long list of potential outcomes. Over three Delphi rounds, a multi-stakeholder panel (patients, clinicians, pharmaceutical company representatives, HTA organizations, payer, and government organization representatives) rated each outcome from 1 (not important to include in a COS) to 9 (essential to include). Outcomes were eliminated or retained based on pre-determined criteria; a special provision to elevate patient priorities was included. An in-person consensus meeting was held after Delphi round 2., Results: Thirty-nine panellists participated. The final COS for prophylaxis treatment included 18 outcomes, seven of which are part of a special subset selected for women, girls and people with the potential to menstruate. There were 11 outcomes in the final perioperative branch COS. Six outcomes overlapped both COS., Conclusions: The coreVWD COS represents a consensus list of outcomes for clinical trials for both factor and non-factor VWD therapies. These outcomes will be useful across the lifecycle of a product, from clinical development through regulatory and market access phases and into patient-provider decision-making., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Evaluating the impact of a year-long external mentorship pilot program in classical hematology.
- Author
-
Qureshy Z, Nair P, Vesely SK, King AA, Lee AI, Connell NT, von Drygalski A, Wong-Sefidan I, Murphy MC, Mistry RH, Zon RL, Reid EG, Fritz J, and Park SJ
- Subjects
- Humans, Pilot Projects, Male, Mentoring methods, Female, Surveys and Questionnaires, Fellowships and Scholarships, Hematology education, Mentors
- Abstract
Abstract: Effective mentorship is a pivotal factor in shaping the career trajectory of trainees interested in classical hematology (CH), which is of critical importance due to the anticipated decline in the CH workforce. However, there is a lack of mentorship opportunities within CH compared with medical oncology. To address this need, a year-long external mentorship program was implemented through the American Society of Hematology Medical Educators Institute. Thirty-five hematology/oncology fellows interested in CH and 34 academically productive faculty mentors from different institutions across North America were paired in a meticulous process that considered individual interests, experiences, and background. Pairs were expected to meet virtually once a month. Participation in a scholarly project was optional. A mixed-methods sequential explanatory design was used to evaluate the program using mentee and mentor surveys, a mentee interview, and a mentee focus group. Thirty-three mentee-mentor pairs (94.2%) completed the program. Sixty-three percent of mentee respondents worked on a scholarly project with their mentor; several mentees earned publications, grants, and awards. Mentee perception that their assigned mentor was a good match was associated with a perceived positive impact on confidence (P = .0423), career development (P = .0423), and professional identity (P = .0302). Furthermore, 23 mentees (66%) accepted CH faculty positions after fellowship. All mentor respondents believed that this program would increase retention in CH. This mentorship program demonstrates a productive, beneficial way of connecting mentees and mentors from different institutions to improve the careers of CH trainees, with the ultimate goal of increasing retention in CH., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Anticoagulation and antiplatelet agent use among patients with von Willebrand disease and cardiac disease.
- Author
-
Merz LE, AbdelHameid D, Kanaan DM, Farah S, Manzo P, and Connell NT
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Platelet Aggregation Inhibitors therapeutic use, von Willebrand Diseases drug therapy, Anticoagulants therapeutic use, Heart Diseases drug therapy, Heart Diseases etiology
- Published
- 2024
- Full Text
- View/download PDF
7. An evolving understanding of low VWF and type 1 VWD.
- Author
-
Connell NT
- Subjects
- von Willebrand Factor genetics
- Published
- 2024
- Full Text
- View/download PDF
8. Factor XIII subunits are stronger together.
- Author
-
Connell NT
- Subjects
- Factor XIII genetics
- Published
- 2024
- Full Text
- View/download PDF
9. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
- Author
-
Virk ZM, Leaf RK, Kuter DJ, Goodarzi K, Connell NT, Connors JM, and Al-Samkari H
- Subjects
- Adult, Humans, Platelet Count, Blood Platelets, Thiazoles adverse effects, Recombinant Fusion Proteins, Thrombopoietin adverse effects, Purpura, Thrombocytopenic, Idiopathic drug therapy, Purpura, Thrombocytopenic, Idiopathic chemically induced, Thiophenes
- Abstract
Avatrombopag is a newer thrombopoietin receptor agonist (TPO-RA) currently approved to treat chronic ITP (duration >12 months). No studies have yet evaluated the safety and effectiveness of avatrombopag in newly diagnosed ITP (duration <3 months) or persistent ITP (duration 3-12 months), and so its use in these populations is presently off-label worldwide. We hypothesize that avatrombopag has similar safety and effectiveness irrespective of ITP disease phase. To evaluate this, we performed a multicenter observational cohort study of adults with ITP treated with avatrombopag, comparing patient outcomes by disease phase (newly diagnosed/persistent versus chronic). Seventy-five patients were included, 23 with newly diagnosed/persistent ITP (17.7 patient-years of avatrombopag treatment) and 52 with chronic ITP (65.3 patient-years of avatrombopag treatment). On avatrombopag, 91% of newly diagnosed/persistent patients versus 96% of chronic patients (p = .58) achieved a platelet response (≥50 × 10
9 /L) and 86% versus 81% of patients (p = .78) achieved a complete response (≥100 × 109 /L). Median platelet counts on avatrombopag were similar between the two groups (165 × 109 /L vs. 129 × 109 /L, p = .57). Response durability was high and similar in both groups. No patients in the newly diagnosed/persistent group had a major bleeding event, thromboembolic event or avatrombopag discontinuation for adverse events, compared with 4, 1, and 2, respectively, in the chronic group. Thrombocytosis (platelets ≥400 × 109 /L) incidence was similar in the two groups. No other drug-related adverse events occurred in either group. Avatrombopag was safe and effective in patients with newly diagnosed and persistent ITP, with outcomes numerically, statistically, and clinically similar to patients receiving avatrombopag for chronic ITP., (© 2023 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
10. Acute myocardial infarction in von Willebrand disease: characteristics and outcomes.
- Author
-
Leiva O, Connors JM, Connell NT, and Berger JS
- Abstract
Background: Von Willebrand disease (VWD) is the most common inherited bleeding disorder. As treatments have improved prognosis of VWD, age-related diseases, including acute myocardial infarction (AMI), have become more prevalent. The treatment of AMI includes antithrombotic therapies, which increase the risk of bleeding. Current guidelines suggest weighing risks/benefits of antithrombotic therapy in patients with VWD. However, data to inform these discussions are lacking., Objective: To characterize outcomes of patients with VWD after AMI., Methods: We conducted a retrospective cohort study utilizing the National Readmissions Database of patients with and without VWD admitted with AMI in 2017 and 2018. Primary outcomes were 90-day any-cause, bleeding-related, and arterial thrombosis-related readmissions. Case-control matching was performed for age, sex (male or female), ST-elevation myocardial infarction, percutaneous coronary intervention, diabetes, and chronic kidney disease. Time-to-event analysis was performed after matching using Cox proportional hazards regression., Results: A total of 136 patients with VWD were matched with 3400 controls without VWD. At 90 days, there were no differences in all-cause (10.7% vs 11.5%; P = 1.00), arterial thrombosis (1.9% vs 3.1%; P = .77), and bleeding (1.9% vs 0.4%; P = .083) readmission in patients with VWD. VWD was associated with increased risk of 90-day bleeding (hazard ratio [HR], 4.75; 95% CI, 1.05-21.66) but not all-cause (HR, 0.91; 95% CI, 0.50-1.67) or arterial thrombosis (HR, 0.54; 95% CI, 0.39-2.19) readmission., Conclusion: Among patients admitted with AMI, VWD was associated with higher risk of 90-day readmission for bleeding but not any-cause and arterial thrombosis-related readmissions. Further studies are needed to balance bleeding and thrombotic risks post-AMI in patients with VWD., Competing Interests: J.C. reports scientific advisory board and consulting fees from Abbott, Anthos, Alnylam, Bristol Myers Squibb, Five Prime Therapeutics, and Pfizer, and research funding from CSL Behring. N.T.C. reports consulting from Takeda and Genentech and honoraria from Octapharma and Equity in Doximity. O.L. and J.S.B. have no competing interests to disclose., (© 2023 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.)
- Published
- 2023
- Full Text
- View/download PDF
11. Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support.
- Author
-
Lee AI, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O'Connell CL, Rajasekhar A, Reynolds RJ, Sharma D, Smith M, Weeks LD, and Erikson CE
- Subjects
- United States epidemiology, Humans, Female, Male, Job Satisfaction, Surveys and Questionnaires, Oncologists, Physicians, Burnout, Professional epidemiology
- Abstract
Burnout is prevalent throughout medicine. Few large-scale studies have examined the impact of physician compensation or clinical support staff on burnout among hematologists and oncologists. In 2019, the American Society of Hematology conducted a practice survey of hematologists and oncologists in the AMA (American Medical Association) Masterfile; burnout was measured using a validated, single-item burnout instrument from the Physician Work-Life Study, while satisfaction was assessed in several domains using a 5-point Likert scale. The overall survey response rate was 25.2% (n = 631). Of 411 respondents with complete responses in the final analysis, 36.7% (n = 151) were from academic practices and 63.3% (n = 260) from community practices; 29.0% (n = 119) were female. Over one-third (36.5%; n = 150) reported burnout, while 12.0% (n = 50) had a high level of burnout. In weighted multivariate logistic regression models incorporating numerous variables, compensation plans based entirely on relative value unit (RVU) generation were significantly associated with high burnout among academic and community physicians, while the combination of RVU + salary compensation showed no significant association. Female gender was associated with high burnout among academic physicians. High advanced practice provider utilization was inversely associated with high burnout among community physicians. Distinct patterns of career dissatisfaction were observed between academic and community physicians. We propose that the implementation of compensation models not based entirely on clinical productivity increased support for women in academic medicine, and expansion of advanced practice provider support in community practices may address burnout among hematologists and oncologists., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. Correctly Establishing and Interpreting Oxygenation Status in Sickle Cell Disease.
- Author
-
Lucas F, Connell NT, and Tolan NV
- Subjects
- Humans, Oximetry methods, Oxyhemoglobins analysis, Hypoxia, Oxygen, Anemia, Sickle Cell complications, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell therapy
- Abstract
Background: As hypoxemia and hypoxia are central elements of disease pathophysiology and disease-related morbidity and mortality in individuals affected by sickle cell disease (SCD), clinical management aims to optimize oxygenation., Content: Hypoxemia is primarily screened for with pulse oximetry. However, in SCD pulse oximetry can inaccurately reflect arterial saturation, posing the risk of undetected (occult) hypoxemia. Solely relying on pulse oximetry might therefore lead to misdiagnosis or mismanagement, with devastating effects on tissue oxygenation. The interpretation of oxygenation status is multifaceted, and "oxygen saturation" is often used as an umbrella term to refer to distinctly different measured quantities-estimated oxygen saturation (O2Sat), hemoglobin oxygen saturation (SO2) by either pulse oximetry or co-oximetry, and fractional oxyhemoglobin (FO2Hb). While in many clinical situations this ambiguous use is of little consequence, O2Sat, SO2, and FO2Hb cannot be used interchangeably in the setting of SCD, as dyshemoglobins, anemia, cardiopulmonary comorbidities, concomitant medications, and frequent transfusions need to be accounted for. This article describes the parameters that determine blood and tissue oxygen concentration, discusses laboratory method performance characteristics and the correct interpretation of currently available clinical laboratory testing, and reviews the literature on noninvasive vs invasive oxygenation measurements in SCD., Summary: By correctly establishing and interpreting oxygenation parameters, clinical and laboratory teams can ensure high-quality, equitable healthcare, counteracting systemic exacerbations of health disparities frequently experienced by individuals with SCD., (© American Association for Clinical Chemistry 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
13. Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.
- Author
-
Arrington-Sanders R, Connell NT, Coon D, Dowshen N, Goldman AL, Goldstein Z, Grimstad F, Javier NM, Kim E, Murphy M, Poteat T, Radix A, Schwartz A, St Amand C, Streed CG Jr, Tangpricha V, Toribio M, and Goldstein RH
- Subjects
- Humans, Gender Identity, Estradiol, Venous Thromboembolism epidemiology, Venous Thromboembolism chemically induced, Transgender Persons psychology, Transsexualism therapy
- Abstract
Objective: Accumulating evidence demonstrates that gender affirming hormone therapy (GAHT) improves mental health outcomes in transgender persons. Data specific to the risks associated with GAHT for transgender persons continue to emerge, allowing for improvements in understanding, predicting, and mitigating adverse outcomes while informing discussion about desired effects. Of particular concern is the risk of venous thromboembolism (VTE) in the context of both longitudinal GAHT and the perioperative setting. Combining what is known about the risk of VTE in cisgender individuals on hormone therapy (HT) with the evidence for transgender persons receiving HT allows for an informed approach to assess underlying risk and improve care in the transgender community., Observations: Hormone formulation, dosing, route, and duration of therapy can impact thromboembolic risk, with transdermal estrogen formulations having the lowest risk. There are no existing risk scores for VTE that consider HT as a possible risk factor. Risk assessment for recurrent VTE and bleeding tendencies using current scores may be helpful when assessing individual risk. Gender affirming surgeries present unique perioperative concerns, and certain procedures include a high likelihood that patients will be on exogenous estrogens at the time of surgery, potentially increasing thromboembolic risk., Conclusions and Relevance: Withholding GAHT due to potential adverse events may cause negative impacts for individual patients. Providers should be knowledgeable about the management of HT in transgender individuals of all ages, as well as in the perioperative setting, to avoid periods in which transgender individuals are off GAHT. Treatment decisions for both anticoagulation and HT should be individualized and tailored to patients' overall goals and desired outcomes, given that the physical and mental health benefits of gender affirming care may outweigh the risk of VTE., (Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
14. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science.
- Author
-
Byams VR, Baker JR, Bailey C, Connell NT, Creary MS, Curtis RG, Dinno A, Guelcher CJ, Kim M, Kulkarni R, Lattimore S, Norris KL, Ramirez L, Skinner MW, Symington S, Tobase P, Vázquez E, Warren BB, Wheat E, and Buckner TW
- Subjects
- Humans, United States, Diversity, Equity, Inclusion, Implementation Science, Health Services, Research, Hemophilia A
- Abstract
Background: The National Hemophilia Foundation (NHF) conducted extensive all-stakeholder inherited bleeding disorder (BD) community consultations to inform a blueprint for future research. Sustaining and expanding the specialized and comprehensive Hemophilia Treatment Center care model, to better serve all people with inherited BDs (PWIBD), and increasing equitable access to optimal health emerged as top priorities., Research Design and Methods: NHF, with the American Thrombosis and Hemostasis Network (ATHN), convened multidisciplinary expert working groups (WG) to distill priority research initiatives from consultation findings. WG5 was charged with prioritizing health services research (HSR); diversity, equity, and inclusion (DEI); and implementation science (IS) research initiatives to advance community-identified priorities., Results: WG5 identified multiple priority research themes and initiatives essential to capitalizing on this potential. Formative studies using qualitative and mixed methods approaches should be conducted to characterize issues and meaningfully investigate interventions. Investment in HSR, DEI and IS education, training, and workforce development are vital., Conclusions: An enormous amount of work is required in the areas of HSR, DEI, and IS, which have received inadequate attention in inherited BDs. This research has great potential to evolve the experiences of PWIBD, deliver transformational community-based care, and advance health equity.
- Published
- 2023
- Full Text
- View/download PDF
15. The Reply.
- Author
-
Barkoudah E, Moss C, and Connell NT
- Published
- 2023
- Full Text
- View/download PDF
16. Beyond the guidelines: how we approach challenging scenarios in the diagnosis and management of von Willebrand disease.
- Author
-
Abou-Ismail MY, James PD, Flood VH, and Connell NT
- Subjects
- Pregnancy, Female, Humans, von Willebrand Factor, Aging, von Willebrand Diseases diagnosis, von Willebrand Diseases therapy
- Abstract
Although von Willebrand disease (VWD) is the most common inherited bleeding disorder, its diagnosis and management are often challenging. Clinical practice guidelines, developed through systematic review of the medical literature and considering the best available evidence, provide guidance for common clinical scenarios. However, in the clinical setting, patients often present with characteristics and nuances that may fall outside the realm of available evidence and guidelines, and hence, shared decision-making will be essential in the evaluation and management of these patients. The challenges in the diagnosis of VWD are mainly attributable to the heterogeneity of the disorder, limitations of laboratory assays, and the significant impact of various physiologic processes on von Willebrand factor. The impact of physiologic normalization of von Willebrand factor, which may occur in various settings such as pregnancy, inflammation, or aging, remains uncertain, as is the optimal management in these scenarios. Multidisciplinary and individualized care, based on evolving evidence supported by clinicians, patients, caregivers, and stakeholders, will be needed to ensure the highest quality care for those who live with VWD., (Copyright © 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
17. Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.
- Author
-
Chen EC, Gibson W, Temoczko P, Connell NT, Handin R, and Parnes AD
- Subjects
- Humans, Factor VIII antagonists & inhibitors, Prospective Studies, Retrospective Studies, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific pharmacology, Hemophilia A drug therapy, Hemostatics
- Abstract
Introduction: Acquired haemophilia A (AHA) is a rare and potentially life-threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment entails achieving haemostasis with bypassing agents or factor replacement, and eradication of the inhibitor with immunosuppressive therapy (IST). Due to the rarity of AHA, there are few prospective data to guide management., Methods: We present a retrospective report of 11 AHA patients treated with emicizumab, a FVIII-mimetic bispecific antibody, administered at 3 mg/kg weekly for 4 weeks in conjunction with rituximab-based immunosuppressive therapy. The chromogenic FVIII inhibitor assay was used to assess for inhibitor eradication., Results: The median follow-up was 13.9 months. The median number of days of additional haemostatic therapy or red blood cell transfusions after initiating emicizumab was 2 (range 0-15). The median was 0 days (range 0-8) for patients who did not require vascular embolization to achieve haemostasis. Eight patients achieved a complete remission (defined as recovery of FVIII activity to > 50% with a negative inhibitor test in the absence of haemostatic and IST); two patients achieved a partial remission (FVIII activity > 50% but with detectable inhibitor); one patient experienced refractory disease. One patient experienced rebleeding and two patients experienced inhibitor recurrence. No thrombotic, thrombotic microangiopathic or infectious complications occurred., Conclusion: Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity immunosuppressive therapies to achieve remission., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
18. Facial Nerve Preservation With Inferior Long-Axis Dissection of Large Vestibular Schwannomas.
- Author
-
Totten DJ, Connell NT, Howser LA, Colomb E, Sandelski MM, Rabbani CC, Savage JJ, Shah MV, and Nelson RF
- Subjects
- Male, Humans, Facial Nerve surgery, Retrospective Studies, Neurosurgical Procedures methods, Treatment Outcome, Postoperative Complications surgery, Neuroma, Acoustic surgery
- Abstract
Objective: To describe a tumor resection using the inferior long-axis (ILA) technique for cisternal facial nerve dissection in large vestibular schwannomas (VS)., Study Design: Retrospective case series from 2018 to 2021., Setting: Tertiary academic medical center., Patients: Patients who underwent surgical resection with ILA facial nerve dissection of VS (>2.0 cm measured parallel to the petrous ridge) and had at least 3-month follow-up., Interventions: Cisternal facial nerve dissection during retrosigmoid or translabyrinthine approach using standardized ILA technique developed by author R.N., Main Outcome Measures: Immediate postoperative and last follow-up facial nerve function with House-Brackmann scores of I to II defined as "good" facial nerve function and House-Brackmann scores III to VI defined as "poor" function. Extent of resection was also assessed., Results: A total of 48 patients underwent large VS resection with ILA dissection of tumor off of the facial nerve from 2018 to 2021. Mean (standard deviation) tumor size was 3.11 (0.76) cm. Mean (standard deviation) follow-up was 9.2 (9.0) months. Gross-total resection or near-total resection were achieved in 75% (radiographic estimate) to 83% (surgeon estimate) of cases. End-of-case facial nerve stimulation at 0.05 mAmp with a response of at least 240 mV was achieved in 80.4% of patients. Good facial nerve function was observed in 72% immediately postoperatively, 70% 1-month postoperatively, and 82% of patients at last follow-up., Conclusions: The ILA technique is now the method of choice of the senior surgeon (R.N.) when performing microsurgical dissection of the cisternal facial nerve, with which he has achieved high rates of total or near-total resection with excellent facial nerve preservation., Competing Interests: The authors disclose no conflicts of interest., (Copyright © 2022, Otology & Neurotology, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
19. A Shear Decline.
- Author
-
Lipsyc-Sharf M, Connell NT, Ostrominski JW, Levy BD, and Loscalzo J
- Subjects
- Humans, Stress, Mechanical, Endothelium, Vascular
- Published
- 2022
- Full Text
- View/download PDF
20. To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin.
- Author
-
Connell NT and Sylvester KW
- Subjects
- Drug Monitoring, Humans, Partial Thromboplastin Time, Anticoagulants pharmacology, Anticoagulants therapeutic use, Heparin therapeutic use
- Abstract
Competing Interests: Declaration of competing interest
- Published
- 2022
- Full Text
- View/download PDF
21. Occam's Razor for Severe B12 Deficiency.
- Author
-
Moss C, Patil DT, Connell NT, Zon RL, and Barkoudah E
- Published
- 2022
- Full Text
- View/download PDF
22. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.
- Author
-
Kalot MA, Husainat N, Abughanimeh O, Diab O, El Alayli A, Tayiem S, Madoukh B, Dimassi A, Qureini A, Ameer B, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle BA, McRae S, Montgomery R, O'Donnell JS, Brignardello-Petersen R, Flood V, Connell NT, James P, and Mustafa RA
- Subjects
- Blood Coagulation Tests, Deamino Arginine Vasopressin therapeutic use, Humans, von Willebrand Factor metabolism, von Willebrand Disease, Type 2, von Willebrand Diseases diagnosis, von Willebrand Diseases drug therapy
- Abstract
von Willebrand Disease (VWD) is associated with significant morbidity because of excessive bleeding. Early diagnosis and treatment are important to prevent and treat these symptoms. We systematically reviewed the accuracy of any von Willebrand factor (VWF) activity assay in the diagnosis and classification of patients for VWD. We searched Cochrane Central, MEDLINE, and EMBASE for eligible studies. The risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 and the certainty of evidence using the GRADE framework. We pooled estimates of sensitivity and specificity. The review included 77 studies that evaluated the use of newer tests of VWF platelet binding activity (VWF:GPIbR, VWF:GPIbM) and VWF:RCo for the diagnosis of VWD (13 studies), VWF propeptide to VWF:Ag ratio, and desmopressin trial for the diagnosis of type 1C VWD (5 studies), VWF multimer analysis and VWF:CB/VWF:Ag ratio for the classification of type 2 VWD (11 studies), genetic testing and ristocetin-induced platelet aggregation to diagnose type 2B VWD (14 studies), genetic testing and FVIII:VWF binding to diagnose type 2N VWD (17 studies). Based on available diagnostic test accuracy, there appear to be comparable test accuracy results between newer tests of platelet binding activity of VWF function and VWF:RCo. The findings of these reviews support VWF multimer analysis or VWF:CB/VWF:Ag to diagnose type 2 VWD. The desmopressin trial test with 1- and 4-hour postinfusion blood work is the test of choice to confirm increased VWF clearance in patients with suspected VWD type 1C. Additionally, genetic testing is most useful in diagnosing type 2B VWD and has a role in the diagnostic algorithm of suspected type 2N VWD., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Response to "The 2021 von Willebrand disease guidelines: Clarity and controversy".
- Author
-
James PD, Connell NT, Flood VH, and Mustafa RA
- Subjects
- Humans, von Willebrand Factor therapeutic use, von Willebrand Diseases
- Published
- 2022
- Full Text
- View/download PDF
24. von Willebrand disease (VWD) and BATs: How do they connect and why should I care?
- Author
-
Valentino LA, Hardy ML, James P, Connell NT, Flood V, Scappe N, and Frick N
- Subjects
- Female, Humans, von Willebrand Factor, Menorrhagia, von Willebrand Diseases diagnosis
- Published
- 2022
- Full Text
- View/download PDF
25. Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review.
- Author
-
El Alayli A, Brignardello Petersen R, Husainat NM, Kalot MA, Aljabiri Y, Turkmani H, Britt A, El-Khechen H, Shahid S, Roller J, Motaghi S, Mansour R, Tosetto A, Abdul-Kadir R, Laffan M, Weyand A, Leebeek FWG, Arapshian A, Kouides P, James P, Connell NT, Flood VH, and Mustafa RA
- Subjects
- Chronic Disease, Epistaxis prevention & control, Hospitalization, Humans, von Willebrand Factor therapeutic use, von Willebrand Diseases complications, von Willebrand Diseases drug therapy
- Abstract
Background: Von Willebrand Disease (VWD) is a common inherited bleeding disorder. Patients with VWD suffering from severe bleeding may benefit from the use of secondary long-term prophylaxis., Aim: Systematically summarize the evidence on the clinical outcomes of secondary long-term prophylaxis in patients with VWD and severe recurrent bleedings., Methods: We searched Medline and EMBASE through October 2019 for relevant randomized clinical trials (RCTs) and comparative observational studies (OS) assessing the effects of secondary long-term prophylaxis in patients with VWD. We used Cochrane Risk of Bias (RoB) tool and the RoB for Non-Randomized Studies of interventions (ROBINS-I) tool to assess the quality of the included studies. We conducted random-effects meta-analyses and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach., Results: We included 12 studies. Evidence from one placebo controlled RCT suggested that VWD prophylaxis as compared to no prophylaxis reduced the rate of bleeding episodes (Rate ratio [RR], .24; 95% confidence interval [CI], .17-.35; low certainty evidence), and of epistaxis (RR, .38; 95%CI, .21-.67; moderate certainty evidence), and may increase serious adverse events RR 2.73 (95%CI .12-59.57; low certainty). Evidence from four before-and-after studies in which researchers reported comparative data suggested that VWD prophylaxis reduced the rate of bleeding (RR .34; 95%CI, .25-.46; very low certainty evidence)., Conclusion: VWD prophylaxis treatment seems to reduce the risk of spontaneous bleeding, epistaxis, and hospitalizations. More RCTs should be conducted to increase the certainty in these benefits., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
26. Speech Recognition Outcomes in Adults With Slim Straight and Slim Modiolar Cochlear Implant Electrode Arrays.
- Author
-
MacPhail ME, Connell NT, Totten DJ, Gray MT, Pisoni D, Yates CW, and Nelson RF
- Subjects
- Adolescent, Adult, Cochlea surgery, Humans, Retrospective Studies, Treatment Outcome, Cochlear Implantation, Cochlear Implants, Speech Perception
- Abstract
Objective: To compare differences in audiologic outcomes between slim modiolar electrode (SME) CI532 and slim lateral wall electrode (SLW) CI522 cochlear implant recipients., Study Design: Retrospective cohort study., Setting: Tertiary academic hospital., Methods: Comparison of postoperative AzBio sentence scores in quiet (percentage correct) in adult cochlear implant recipients with SME or SLW matched for preoperative AzBio sentence scores in quiet and aided and unaided pure tone average., Results: Patients with SLW (n = 52) and patients with SME (n = 37) had a similar mean (SD) age (62.0 [18.2] vs 62.6 [14.6] years, respectively), mean preoperative aided pure tone average (55.9 [20.4] vs 58.1 [16.4] dB; P = .59), and mean AzBio score (percentage correct, 11.1% [13.3%] vs 8.0% [11.5%]; P = .25). At last follow-up (SLW vs SME, 9.0 [2.9] vs 9.9 [2.6] months), postoperative mean AzBio scores in quiet were not significantly different (percentage correct, 70.8% [21.3%] vs 65.6% [24.5%]; P = .29), and data log usage was similar (12.9 [4.0] vs 11.3 [4.1] hours; P = .07). In patients with preoperative AzBio <10% correct, the 6-month mean AzBio scores were significantly better with SLW than SME (percentage correct, 70.6% [22.9%] vs 53.9% [30.3%]; P = .02). The intraoperative tip rollover rate was 8% for SME and 0% for SLW., Conclusions: Cochlear implantation with SLW and SME provides comparable improvement in audiologic functioning. SME does not exhibit superior speech recognition outcomes when compared with SLW.
- Published
- 2022
- Full Text
- View/download PDF
27. Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System.
- Author
-
Dosani T, Xiang J, Wang K, Deng Y, Connell NT, Connery D, Levin F, Roy A, Wadia RJ, Wong EY, and Rose MG
- Subjects
- Electronics, Humans, Retrospective Studies, Delivery of Health Care, Integrated, Hematology, Remote Consultation
- Abstract
Introduction: Electronic consultations (e-consults) may be a valuable tool in the current era of increased demand for hematologists. Despite the increasing use of e-consults in hematology, their optimal utilization and impact on patient outcomes and workload are largely unknown., Methods: In this retrospective cohort study, we studied the hematology consult experience at Veterans Affairs Connecticut from 2006 to 2018. We included 7,664 hematology consults (3,240 e-consults and 4,424 face-to-face [FTF] consults) requested by 1,089 unique clinicians., Results: We found that e-consults were rapidly adopted and used equally among physicians of different degrees of experience. The number of FTF consults did not decrease after the introduction of e-consult services. E-consults were preferentially used for milder laboratory abnormalities that had been less likely to result in a consult before their availability. Referring clinicians used e-consults preferentially for periprocedural management, anemia, leukopenia, and anticoagulation questions. Eighty-three percent of e-consults were resolved without needing an FTF visit in the year after the consult. Consults for pancytopenia, gammopathy, leukocytosis, and for patients with known malignancy were less likely to be resolved by e-consult. Among patients who were diagnosed with a new hematologic malignancy after their consult, having an e-consult before an FTF visit did not adversely affect survival., Conclusion: In summary, e-consults safely expanded delivery of hematology services in our health care system but increased total consult volume. We report novel data on what types of consults may be best suited to the electronic modality, the impact of e-consults on workload, and their optimal use and implementation., Competing Interests: Nathan T. ConnellStock and Other Ownership Interests: Doximity Michal G. RoseResearch Funding: Lilly (Inst), Oncocyte (Inst), BMS (Inst), EpicentRx (Inst), Janssen (Inst)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
28. Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome.
- Author
-
Goyal A, Narayanan D, Wong W, Laga AC, Connell NT, Ritter SY, and Cobos G
- Abstract
Competing Interests: None disclosed.
- Published
- 2022
- Full Text
- View/download PDF
29. Use of Social Media in the Practice of Medicine.
- Author
-
Connell NT, Weyand AC, and Barnes GD
- Subjects
- Education, Medical, Humans, Professionalism, Delivery of Health Care, Physicians, Social Media
- Published
- 2022
- Full Text
- View/download PDF
30. Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature.
- Author
-
Brignardello-Petersen R, El Alayli A, Husainat N, Kalot MA, Shahid S, Aljabirii Y, Britt A, Alturkmani H, El-Khechen H, Motaghi S, Roller J, Abdul-Kadir R, Couper S, Kouides P, Lavin M, Ozelo MC, Weyand A, James PD, Connell NT, Flood VH, and Mustafa RA
- Subjects
- Female, Humans, Pregnancy, Systematic Reviews as Topic, von Willebrand Factor, Menorrhagia, Postpartum Hemorrhage drug therapy, Postpartum Hemorrhage etiology, Tranexamic Acid therapeutic use, von Willebrand Diseases complications, von Willebrand Diseases drug therapy
- Abstract
von Willebrand disease (VWD) disproportionately affects women because of the potential for heavy menstrual bleeding (HMB), delivery complications, and postpartum hemorrhage (PPH). To systematically synthesize the evidence regarding first-line management of HMB, treatment of women requiring or desiring neuraxial analgesia, and management of PPH. We searched Medline and EMBASE through October 2019 for randomized trials, comparative observational studies, and case series comparing the effects of desmopressin, hormonal therapy, and tranexamic acid (TxA) on HMB; comparing different von Willebrand factor (VWF) levels in women with VWD who were undergoing labor and receiving neuraxial anesthesia; and measuring the effects of TxA on PPH. We conducted duplicate study selection, data abstraction, and appraisal of risk of bias. Whenever possible, we conducted meta-analyses. We assessed the quality of the evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. We included 1 randomized trial, 3 comparative observational studies, and 10 case series. Moderate-certainty evidence showed that desmopressin resulted in a smaller reduction of menstrual blood loss (difference in mean change from baseline, 41.6 [95% confidence interval, 16.6-63.6] points in a pictorial blood assessment chart score) as compared with TxA. There was very-low-certainty evidence about how first-line treatments compare against each other, the effects of different VWF levels in women receiving neuraxial anesthesia, and the effects of postpartum administration of TxA. Most of the evidence relevant to the gynecologic and obstetric management of women with VWD addressed by most guidelines is very low quality. Future studies that address research priorities will be key when updating such guidelines., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
- Author
-
Kalot MA, Husainat N, El Alayli A, Abughanimeh O, Diab O, Tayiem S, Madoukh B, Dimassi AB, Qureini A, Ameer B, Eikenboom JCJ, Giraud N, McLintock C, McRae S, Montgomery RR, O'Donnell JS, Scappe N, Sidonio RF, Brignardello-Petersen R, Flood VH, Connell NT, James PD, and Mustafa RA
- Subjects
- Blood Coagulation Tests, Hemorrhage diagnosis, Hemorrhage etiology, Humans, von Willebrand Factor analysis, von Willebrand Disease, Type 1 diagnosis, von Willebrand Diseases diagnosis
- Abstract
von Willebrand disease (VWD) is associated with significant morbidity as a result of excessive mucocutaneous bleeding. Early diagnosis and treatment are important to prevent and treat these symptoms. We systematically reviewed the accuracy of diagnostic tests using different cutoff values of von Willebrand factor antigen (VWF:Ag) and platelet-dependent von Willebrand factor (VWF) activity assays in the diagnosis of VWD. We searched Cochrane Central Register for Controlled Trials, MEDLINE, and Embase databases for eligible studies. We pooled estimates of sensitivity and specificity and reported patient-important outcomes when relevant. This review included 21 studies that evaluated VWD diagnosis. The results showed low certainty in the evidence for a net health benefit from reconsidering the diagnosis of VWD vs removing the disease diagnosis in patients with VWF levels that have normalized with age. For the diagnosis of type 1 VWD, VWF sequence variants were detected in 75% to 82% of patients with VWF:Ag < 0.30 IU/mL and in 44% to 60% of patients with VWF:Ag between 0.30 and 0.50 IU/mL. A sensitivity of 0.90 (95% confidence interval [CI], 0.83-0.94) and a specificity of 0.91 (95% CI, 0.76-0.97) were observed for a platelet-dependent VWF activity/VWF:Ag ratio < 0.7 in detecting type 2 VWD (moderate certainty in the test accuracy results). VWF:Ag and platelet-dependent activity are continuous variables that are associated with an increase in bleeding risk with decreasing levels. This systematic review shows that using a VWF activity/VWF:Ag ratio < 0.7 vs lower cutoff levels in patients with an abnormal initial VWD screen is more accurate for the diagnosis of type 2 VWD., (© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
32. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature.
- Author
-
Brignardello-Petersen R, El Alayli A, Husainat N, Kalot M, Shahid S, Aljabirii Y, Britt A, Alturkmani H, El-Khechen H, Motaghi S, Roller J, Dimassi A, Abughanimeh O, Madoukh B, Arapshian A, Grow JM, Kouides P, Laffan M, Leebeek FWG, O'Brien SH, Tosetto A, James PD, Connell NT, Flood V, and Mustafa RA
- Subjects
- Factor VIII therapeutic use, Hemostasis, Humans, von Willebrand Factor therapeutic use, Tranexamic Acid therapeutic use, von Willebrand Diseases complications
- Abstract
von Willebrand disease (VWD) is the most common inherited bleeding disorder. The management of patients with VWD who are undergoing surgeries is crucial to prevent bleeding complications. We systematically summarized the evidence on the management of patients with VWD who are undergoing major and minor surgeries to support the development of practice guidelines. We searched Medline and EMBASE from inception through October 2019 for randomized clinical trials (RCTs), comparative observational studies, and case series that compared maintaining factor VIII (FVIII) levels or von Willebrand factor (VWF) levels at >0.50 IU/mL for at least 3 days in patients undergoing major surgery, and those with options for perioperative management of patients undergoing minor surgery. Two authors screened and abstracted data and assessed the risk of bias. We conducted meta-analyses when possible. We evaluated the certainty of the evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. We included 7 case series for major surgeries and 2 RCTs and 12 case series for minor surgeries. Very-low-certainty evidence showed that maintaining FVIII levels or VWF levels of >0.50 IU/mL for at least 3 consecutive days showed excellent hemostatic efficacy (as labeled by the researchers) after 74% to 100% of major surgeries. Low- to very-low-certainty evidence showed that prescribing tranexamic acid and increasing VWF levels to 0.50 IU/mL resulted in fewer bleeding complications after minor procedures compared with increasing VWF levels to 0.50 IU/mL alone. Given the low-quality evidence for guiding management decisions, a shared-decision model leading to individualized therapy plans will be important in patients with VWD who are undergoing surgical and invasive procedures., (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy.
- Author
-
Kalot MA, Husainat N, Tayiem S, El Alayli A, Dimassi AB, Diab O, Abughanimeh O, Madoukh B, Qureini A, Ameer B, Di Paola J, Eikenboom JCJ, Jacobs-Pratt V, McLintock C, Montgomery R, O'Donnell JS, Sidonio R, Brignardello-Petersen R, Flood V, Connell NT, James PD, and Mustafa RA
- Subjects
- Adult, Bias, Child, Cohort Studies, Humans, Mass Screening, Sensitivity and Specificity, von Willebrand Diseases diagnosis
- Abstract
Von Willebrand disease (VWD) can be associated with significant morbidity. Patients with VWD can experience bruising, mucocutaneous bleeding, and bleeding after dental and surgical procedures. Early diagnosis and treatment are important to minimize the risk of these complications. Several bleeding assessment tools (BATs) have been used to quantify bleeding symptoms as a screening tool for VWD. We systematically reviewed diagnostic test accuracy results of BATs to screen patients for VWD. We searched Cochrane Central, MEDLINE, and EMBASE for eligible studies, reference lists of relevant reviews, registered trials, and relevant conference proceedings. Two investigators screened and abstracted data. Risk of bias was assessed using the revised tool for the quality assessment of diagnostic accuracy studies and certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework. We pooled estimates of sensitivity and specificity. The review included 7 cohort studies that evaluated the use of BATs to screen adult and pediatric patients for VWD. The pooled estimates for sensitivity and specificity were 75% (95% confidence interval, 66-83) and 54% (29-77), respectively. Certainty of evidence varied from moderate to high. This systematic review provides accuracy estimates for validated BATs as a screening modality for VWD. A BAT is a useful initial screening test to determine who needs specific blood testing. The pretest probability of VWD (often determined by the clinical setting/patient population), along with sensitivity and specificity estimates, will influence patient management., (© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. How to manage bleeding disorders in aging patients needing surgery.
- Author
-
Abou-Ismail MY and Connell NT
- Subjects
- Age Factors, Aged, 80 and over, Aging, Factor XI Deficiency therapy, Female, Hemophilia A therapy, Hemostasis drug effects, Humans, Male, von Willebrand Diseases therapy, Hemorrhage therapy, Perioperative Care methods
- Abstract
With improvements in medical care, the life expectancy of patients with bleeding disorders is approaching that of the general population. A growing population of older adult patients with bleeding disorders is at risk of age-related comorbidities and in need of various elective and emergent age-related procedures. The increased risk of thrombosis and volume overload in older adults complicates perioperative hemostatic management. Furthermore, antithrombotic treatment such as antiplatelet or anticoagulant therapy, which is frequently required for various cardiovascular interventions, requires a meticulous individualized approach. Evidence-based guidelines for the management of aging patients with bleeding disorders are lacking, largely due to the underrepresentation of older adult patients in clinical trials as well as the rarity of many such bleeding disorders. We discuss the current guidelines and recommendations in the perioperative hemostatic management of older adult patients with hemophilia and von Willebrand disease as well as other rare bleeding disorders. The optimal management of these patients is often complex and requires a thorough multidisciplinary and individualized approach involving hematologists, surgeons, anesthesiologists, and the specialists treating the underlying disorder., (Copyright © 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
35. Inherited Bleeding Disorders.
- Author
-
Connell NT
- Subjects
- Blood Platelet Disorders, Humans, Blood Coagulation Disorders, Inherited diagnosis, Blood Coagulation Disorders, Inherited epidemiology, Blood Coagulation Disorders, Inherited genetics
- Published
- 2021
- Full Text
- View/download PDF
36. Acquired von Willebrand Syndrome.
- Author
-
Langer AL and Connell NT
- Subjects
- Aortic Valve Stenosis, Humans, von Willebrand Factor, von Willebrand Diseases therapy
- Abstract
Acquired von Willebrand syndrome can occur in the setting of myeloproliferative neoplasms; plasma cell dyscrasias and other lymphoproliferative disorders; autoimmune conditions; and causes of increased shear forces, such as aortic stenosis or other structural heart disease and mechanical circulatory support. The depletion of von Willebrand factor, especially high-molecular-weight multimers, can lead to mucocutaneous bleeding and the formation of arteriovenous malformations, particularly in the gastrointestinal tract. Management focuses on correction of the underlying cause when possible, but may include intravenous immunoglobulins, von Willebrand factor concentrate, rituximab, or antiangiogenic therapy depending on the clinical context., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization.
- Author
-
Tuttle KL, Stavrou E, Hong DIC, Connell NT, and Wickner P
- Subjects
- Adult, Antineoplastic Agents immunology, Antineoplastic Agents therapeutic use, Colonic Neoplasms drug therapy, Female, Hemorrhage etiology, Humans, Male, Middle Aged, Organoplatinum Compounds adverse effects, Organoplatinum Compounds immunology, Organoplatinum Compounds therapeutic use, Oxaliplatin adverse effects, Oxaliplatin therapeutic use, Platelet Count, Blood Platelets immunology, Desensitization, Immunologic methods, Drug Hypersensitivity immunology, Oxaliplatin immunology, Thrombocytopenia pathology
- Published
- 2021
- Full Text
- View/download PDF
38. Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis.
- Author
-
Moll M, Zon RL, Sylvester KW, Rimsans J, Chen EC, Ghosh AJ, Abston E, Kim A, Rutherford H, Mitre X, Hakim A, Connell NT, Battinelli E, Fredenburgh LE, Baron RM, Hobbs BD, Cho MH, Mittleman MA, Woolley AE, and Connors JM
- Subjects
- Anticoagulants therapeutic use, Humans, Intensive Care Units, Propensity Score, Retrospective Studies, SARS-CoV-2, COVID-19, Heparin
- Published
- 2021
- Full Text
- View/download PDF
39. Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study.
- Author
-
Weeks LD, Sylvester KW, Connors JM, and Connell NT
- Abstract
Background: Patients hospitalized with severe acute respiratory syndrome coronavirus 2 infection are at risk for thrombotic complications necessitating use of therapeutic unfractionated heparin (UFH). Full-dose anticoagulation limits requirements for organ support interventions in moderately ill patients with coronavirus disease 2019 (COVID-19). Given this benefit, it is important to evaluate response to therapeutic anticoagulation in this population., Objectives: The aim of this study was to assess therapeutic UFH infusions and associated bleeding risk in patients with COVID-19., Patients/methods: This retrospective cohort study includes patients at Brigham and Women's Hospital, Boston, Massachusetts, receiving weight-based nursing-nomogram titrated UFH infusion during a 10-week surge in COVID-19 hospitalizations. Of 358 patients on therapeutic UFH during this interval, 97 (27.1%) had confirmed COVID-19. Patient characteristics, laboratory values, and information regarding UFH infusion and bleeding events were obtained from the electronic medical record., Results: Patients who were COVID-19 positive had fewer therapeutic activatrd partial thromboplastin times (aPTTs) compared to COVID-19-negative patients (median rate, 40.0% vs 53.1%; P < .0005). Both major and clinically relevant nonmajor bleeding were increased in COVID-19-positive patients, with major bleeding observed in 10.3% (95% confidence interval [CI], 5.7%-17.9%) of patients who were COVID-19 positive and 3.1% (95% CI, 1.6%-5.9%) of patients who were COVID-19 negative ( P < .005). In logistic regression, bleeding events were associated with receiving UFH for longer than 7 days, but not platelet count, coagulation, or inflammatory measurements., Conclusions: Our data indicate a higher incidence of bleeding complications in patients with COVID-19 receiving weight-based nursing-nomogram titrated UFH infusions despite a higher prevalence of subtherapeutic aPTTs in this population. These data underscore the need for prospective studies aimed at improving the quality and safety of therapeutic anticoagulation in patients with COVID-19., (© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)
- Published
- 2021
- Full Text
- View/download PDF
40. Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection.
- Author
-
Pozdnyakova O, Connell NT, Battinelli EM, Connors JM, Fell G, and Kim AS
- Subjects
- Aged, Blood Cell Count, COVID-19 pathology, Critical Illness, Disease Progression, Female, Humans, Leukocyte Count, Male, Middle Aged, SARS-CoV-2, COVID-19 blood, COVID-19 complications, Leukocytes pathology, Lymphopenia virology, Neutrophils pathology
- Abstract
Objectives: To investigate the clinical significance of numeric and morphologic peripheral blood (PB) changes in coronavirus disease 2019 (COVID-19)-positive patients in predicting the outcome, as well as to compare these changes between critically ill COVID-19-positive and COVID-19-negative patients., Methods: The study included 90 COVID-19-positive (51 intensive care unit [ICU] and 39 non-ICU) patients and 30 COVID-19-negative ICU patients. We collected CBC parameters (both standard and research) and PB morphologic findings, which were independently scored by two hematopathologists., Results: All patients with COVID-19 demonstrated striking numeric and morphologic WBC changes, which were different between mild and severe disease states. More severe disease was associated with significant neutrophilia and lymphopenia, which was intensified in critically ill patients. Abnormal WBC morphology, most pronounced in monocytes and lymphocytes, was associated with more mild disease; the changes were lost with disease progression. Between COVID-19-positive and COVID-19-negative ICU patients, significant differences in morphology-associated research parameters were indicative of changes due to the severe acute respiratory syndrome coronavirus 2 virus, including higher RNA content in monocytes, lower RNA content in lymphocytes, and smaller hypogranular neutrophils., Conclusions: Hospitalized patients with COVID-19 should undergo a comprehensive daily CBC with manual WBC differential to monitor for numerical and morphologic changes predictive of poor outcome and signs of disease progression., (© American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
41. von Willebrand disease: proposing definitions for future research.
- Author
-
Connell NT, James PD, Brignardello-Petersen R, Abdul-Kadir R, Ameer B, Arapshian A, Couper S, Di Paola J, Eikenboom J, Giraud N, Grow JM, Haberichter S, Jacobs-Pratt V, Konkle BA, Kouides P, Laffan M, Lavin M, Leebeek FWG, McLintock C, McRae S, Montgomery R, O'Brien SH, O'Donnell JS, Ozelo MC, Scappe N, Sidonio R, Tosetto A, Weyand AC, Kalot MA, Husainat N, Mustafa RA, and Flood VH
- Subjects
- Humans, von Willebrand Factor genetics, von Willebrand Diseases diagnosis, von Willebrand Diseases epidemiology
- Published
- 2021
- Full Text
- View/download PDF
42. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
- Author
-
Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, Grow JM, Kouides P, Laffan M, Lavin M, Leebeek FWG, O'Brien SH, Ozelo MC, Tosetto A, Weyand AC, James PD, Kalot MA, Husainat N, and Mustafa RA
- Subjects
- Female, Hemostasis, Humans, Hemophilia A, Thrombosis, Venous Thromboembolism, von Willebrand Diseases diagnosis, von Willebrand Diseases therapy
- Abstract
Background: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients., Objective: These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD., Methods: ASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment., Results: The panel agreed on 12 recommendations and outlined future research priorities., Conclusions: These guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
43. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.
- Author
-
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, and Mustafa RA
- Subjects
- Hemorrhage, Hemostasis, Humans, Hemophilia A, Thrombosis, von Willebrand Diseases diagnosis
- Abstract
Background: von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans. Accurate and timely diagnosis presents numerous challenges., Objective: These evidence-based guidelines of the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis., Methods: ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that included 4 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical Center (KUMC) supported the guideline-development process, including performing or updating systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently subject to public comment., Results: The panel agreed on 11 recommendations., Conclusions: Key recommendations of these guidelines include the role of bleeding-assessment tools in the assessment of patients suspected of VWD, diagnostic assays and laboratory cutoffs for type 1 and type 2 VWD, how to approach a type 1 VWD patient with normalized levels over time, and the role of genetic testing vs phenotypic assays for types 2B and 2N. Future critical research priorities are also identified., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
44. VTE in ICU Patients With COVID-19.
- Author
-
Moll M, Zon RL, Sylvester KW, Chen EC, Cheng V, Connell NT, Fredenburgh LE, Baron RM, Cho MH, Woolley AE, and Connors JM
- Subjects
- Adult, Aged, Anticoagulants therapeutic use, Betacoronavirus, C-Reactive Protein metabolism, COVID-19, Computed Tomography Angiography, Coronavirus Infections physiopathology, Coronavirus Infections therapy, Enoxaparin therapeutic use, Female, Ferritins blood, Fibrin Fibrinogen Degradation Products metabolism, Fibrinogen metabolism, Heparin therapeutic use, Humans, Incidence, L-Lactate Dehydrogenase blood, Male, Middle Aged, Pandemics, Partial Thromboplastin Time, Pneumonia, Viral physiopathology, Pneumonia, Viral therapy, Prothrombin Time, Pulmonary Embolism blood, Pulmonary Embolism diagnostic imaging, Pulmonary Embolism prevention & control, SARS-CoV-2, Severity of Illness Index, Ultrasonography, Venous Thromboembolism blood, Venous Thromboembolism diagnostic imaging, Venous Thromboembolism epidemiology, Venous Thromboembolism prevention & control, Venous Thrombosis blood, Venous Thrombosis diagnostic imaging, Venous Thrombosis prevention & control, Coronavirus Infections blood, Intensive Care Units, Pneumonia, Viral blood, Pulmonary Embolism epidemiology, Venous Thrombosis epidemiology
- Published
- 2020
- Full Text
- View/download PDF
45. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia.
- Author
-
How J, Leiva O, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Zwicker JI, Fogerty AE, and Hobbs GS
- Subjects
- Adult, Female, Humans, Platelet Count, Pregnancy, Risk Factors, Abortion, Spontaneous, Live Birth, Models, Biological, Pregnancy Complications, Hematologic blood, Pregnancy Complications, Hematologic drug therapy, Pregnancy Complications, Hematologic epidemiology, Thrombocythemia, Essential blood, Thrombocythemia, Essential drug therapy, Thrombocythemia, Essential epidemiology
- Abstract
Pregnancy in essential thrombocythemia (ET) is associated with increased risk of obstetric complications. We retrospectively evaluated risk factors in 121 pregnancies in 52 ET women seen at 3 affiliate hospitals. Univariable and multivariable analyses were performed at the α = 0.10 level. Cell counts were characterized throughout pregnancy and correlated with outcomes using logistic modeling. The overall live birth rate was 69 %. 48.7 % of all women experienced a pregnancy complication, the most common being spontaneous abortion, which occurred in 26 % of all pregnancies. Maternal thrombosis and hemorrhage rates were 2.5 % and 5.8 %. On multivariable analysis, aspirin use (OR 0.29, p = 0.014, 90 % CI 0.118-0.658) and history of prior pregnancy loss (OR 3.86, p = 0.011, CI 1.49-9.15) were associated with decreased and increased pregnancy complications, respectively. A Markov model was used to analyze the probability of a future pregnancy complication based on initial pregnancy outcome. An ET woman who suffers a pregnancy complication has a 0.594 probability of a subsequent pregnancy complication, compared to a 0.367 probability if she didn't suffer a complication. However, despite this elevated risk, overall prognosis is good, with a >50 % probability of a successful pregnancy by the third attempt. Platelet counts decreased by 43 % in ET during pregnancy, with nadir at delivery and prompt recovery in the postpartum period. Women with larger declines in gestational platelet counts were less likely to suffer complications (p = 0.083). Our study provides important guidance to physicians treating ET women during pregnancy, including counseling information regarding risk assessment and expected trajectory of platelet levels., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
46. Systems-based hematology: highlighting successes and next steps.
- Author
-
May JE, Irelan PC, Boedeker K, Cahill E, Fein S, Garcia DA, Hicks LK, Lawson J, Lim MY, Morton CT, Rajasekhar A, Shanbhag S, Zumberg MS, Plovnick RM, and Connell NT
- Subjects
- Delivery of Health Care, Humans, Hematologic Diseases diagnosis, Hematologic Diseases therapy, Hematology
- Abstract
Systems-based hematology is dedicated to improving care delivery for patients with blood disorders. First defined by the American Society of Hematology in 2015, the idea of a systems-based hematologist arose from evolving pressures in the health care system and increasing recognition of opportunities to optimize the quality and cost effectiveness of hematologic care. In this review, we begin with a proposed framework to formalize the discussion of the range of initiatives within systems-based hematology. Classification by 2 criteria, project scope and method of intervention, facilitates comparison between initiatives and supports dialogue for future efforts. Next, we present published examples of successful systems-based initiatives in the field of hematology, including efforts to improve stewardship in the diagnosis and management of complex hematologic disorders (eg, heparin-induced thrombocytopenia and thrombophilias), the development of programs to promote appropriate use of hematologic therapies (eg, blood products, inferior vena cava filters, and anticoagulation), changes in care delivery infrastructure to improve access to hematologic expertise (eg, electronic consultation and disorder-specific care pathways), and others. The range of projects illustrates the broad potential for interventions and highlights different metrics used to quantify improvements in care delivery. We conclude with a discussion about future directions for the field of systems-based hematology, including extension to malignant disorders and the need to define, expand, and support career pathways., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
47. Coagulopathy of COVID-19 and antiphospholipid antibodies.
- Author
-
Connell NT, Battinelli EM, and Connors JM
- Published
- 2020
- Full Text
- View/download PDF
48. Venous thromboembolism in the hormonal milieu.
- Author
-
Connell NT and Connors JM
- Subjects
- Contraceptives, Oral, Hormonal pharmacology, Female, Humans, Pregnancy, Risk Factors, Contraceptives, Oral, Hormonal adverse effects, Venous Thromboembolism chemically induced
- Abstract
Purpose of Review: Hormonal therapy is administered for multiple indications including contraception, alleviation of menopausal symptoms, hypogonadism, and more recently, gender-affirming care. Data suggest varying degrees of increased risk for venous thromboembolism (VTE)., Recent Findings: While oral progestin only methods do not appear to increase the risk of VTE, an association was seen with injection progestin contraception. Combined oral contraception with low-dose ethinyl estradiol and most types of progestin increased the risk of VTE compared with levonorgestrel-containing oral therapies. While transdermal hormonal contraception has been previously associated with increased VTE, a recently approved levonorgestrel and ethinyl estradiol transdermal patch reported low rates (<0.2%) in a large single-arm open-label study. Women receiving postmenopausal HRT experienced an increased risk of VTE in a dose-dependent manner when using oral hormonal therapy while nonoral methods, such as topical estrogen, did not appear to increase the risk of VTE. Some studies suggest no increased risk of VTE with testosterone therapy, however, a recent case-crossover study suggested higher VTE risk in men on testosterone, particularly men less than age 65 without hypogonadism. Route of administration had no effect on VTE rates. The estimated incidence rate of VTE risk in transgender women receiving estrogen therapy is 2.3 per 1000 person years, but may be imprecise due to heterogeneity in studies included in published meta-analyses. Surgical risk estimates are primarily indirect data drawn from cisgender patients receiving hormone therapy in the perioperative setting., Summary: Hormonal therapy affects VTE risk to varying degrees dependent on specific type of hormone, formulation, and occasionally route of delivery.
- Published
- 2020
- Full Text
- View/download PDF
49. Taken the wrong way, a complement becomes catastrophic.
- Author
-
Connell NT
- Subjects
- Humans, Mutation, Complement System Proteins, Thrombosis
- Published
- 2020
- Full Text
- View/download PDF
50. An international survey to inform priorities for new guidelines on von Willebrand disease.
- Author
-
Kalot MA, Al-Khatib M, Connell NT, Flood V, Brignardello-Petersen R, James P, and Mustafa RA
- Subjects
- Caregivers, Female, Geography, Humans, Male, von Willebrand Diseases diagnosis, von Willebrand Diseases therapy, Internationality, Practice Guidelines as Topic, Surveys and Questionnaires, von Willebrand Diseases epidemiology
- Abstract
Introduction: von Willebrand disease (VWD) is an inherited bleeding disorder caused by a quantitative or qualitative dysfunction of von Willebrand factor. Clinicians, patients and other stakeholders have many questions about the diagnosis and management of the disease., Aim: To identify topics of highest importance to stakeholders that could be addressed by guidelines to be developed by the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF) and the World Federation of Hemophilia (WFH)., Methods: A survey to determine and prioritize topics to be addressed in the collaborative development of guidelines for VWD was distributed to international stakeholders including patients, caregivers and healthcare providers (HCPs). Representatives of the four organizations coordinated the distribution strategy. The survey focused on both diagnosis and management of VWD, soliciting 7-point Likert-scale responses and open-ended comments, in English, French and Spanish. We conducted descriptive analysis with comparison of results by stakeholder type, gender and countries' income classification for the rating questions and qualitative conventional content data analysis for the open-ended responses., Results: A total of 601 participants responded to the survey (49% patients/caregivers and 51% healthcare providers). The highest priority topics identified were diagnostic criteria/classification, bleeding assessment tools and treatment options for women and surgical patients. In contrast, screening for anaemia and differentiating plasma-derived therapy versus recombinant therapies received lower ratings., Conclusion: This survey highlighted areas of importance to a diverse representation of stakeholders in the diagnosis and management of VWD, providing a framework for future guideline development and implementation., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.